France Cardiovascular Diseases Therapeutics Market Analysis

France Cardiovascular Disease Therapeutics Market Executive Analysis

The France cardiovascular disease therapeutics market size is at around $4.47 Bn in 2022 and is projected to reach $7.24 Bn in 2030, exhibiting a CAGR of 6.22% during the forecast period. The French pharmaceutical industry has criticized government plans to establish a 2023 spending cap on medications that is 7% less than the actual 2022 spending. In an attempt to reduce the cost of prescription drugs by $1.1 Bn in 2019, the government is also preparing a number of price reductions for medications as well as an increase in what the industry association Leem refers to as a "confiscatory" sales tax. According to the social security funding bill for 2023, the total amount of state spending on reimbursed medicines in that year will not exceed $26.3 Bn, down from an anticipated $28.2 Bn in 2018. The bill's suggested savings of $1.18 Bn are anticipated to be achieved through price reductions on reimbursed medications and other medical supplies and the balance via the so-called "safeguard clause," which entails businesses paying rebates to the healthcare system if their sales surpass pre-determined thresholds.

In France, cardiovascular diseases (CVDs), which account for 27% of the 535,000 fatalities, are the second largest cause of death. More specifically, 7% of deaths were caused by ischaemic heart disease, and 6% by cerebrovascular disease; the male-to-female ratios for these last two causes of mortality were 2.4 and 1.3, respectively.

In France, a class of medications known as statins are used to lower blood cholesterol levels, which can help lower the chance of heart attack and stroke. Patients with elevated cholesterol or other CVD risk factors frequently receive them as prescriptions. By preventing blood clots from forming, antiplatelet medications like aspirin or clopidogrel can lower the chance of having a heart attack or stroke. Patients with a history of CVD or those who are at a high risk of getting the condition are frequently prescribed them. Beta-blockers are used to manage heart failure and angina, in addition to high blood pressure and other conditions. They function by lowering the pulse rate and easing the strain on the heart. Another group of medications called calcium channel blockers is used to address both angina and high blood pressure. They relieve the strain on the heart by relaxing blood arteries. A more recent class of medications called PCSK9 inhibitors is used to reduce blood cholesterol levels. They function by preventing the activity of PCSK9, an enzyme that aids in controlling cholesterol levels.

Market Dynamics

Market Growth Drivers

In France, CVD is a significant contributor to morbidity and fatality, accounting for about one-third of the total number of deaths. Due to factors like an aging population and an increase in risk factors like obesity, diabetes, and high blood pressure, it is anticipated that the frequency of CVD will rise in the upcoming years. The France cardiovascular disease market is anticipated to rise as a result. The aging population and rising healthcare expenses are two factors that are driving up healthcare spending in France. The demand for these medications is anticipated to rise as a result of increased accessibility and affordability of CVD therapeutics.

Market Restraints

Drug prices are regulated by the French government, and reimbursement for treatments for CVD is governed by stringent rules. This may restrict both patient access to certain treatments as well as the profitability of particular medicines. Alternative therapies for CVD include surgical methods as well as dietary and exercise modifications. Patients might favor these non-traditional therapies, especially if they are less invasive or come with fewer adverse effects than drug therapies thereby limiting the expansion of the France cardiovascular disease therapeutics market.

Competitive Landscape

Key Players

• Polygon Therapeutics (FRA)- A French biotech firm called POLYGON Therapeutics is creating cutting-edge medications for patients with cardiovascular diseases. PLG-101, a first-in-class monoclonal antibody, is the company's primary medication.
• Enyo Pharma (FRA)
• MaaT Pharma (FRA)
• Medac (FRA)
• Laboratoires Boiron (FRA)
• AstraZeneca
• Sanofi
• Novartis
• Merck
• Gilead Sciences
• F. Hoffmann-La Roche

Notable Deals

September 2022- A 18-month agreement is signed by Polygon Therapeutics and Inserm Transfert for a joint study on cardiovascular diseases. In order to produce novel preclinical data for upcoming clinical trials, this research collaboration will incorporate the "Immuno-metabolic mechanisms of cardiovascular diseases" team at the Paris Cardiovascular Research Center.

Healthcare Policies and Regulatory Landscape

The Assurance Maladie is France's state healthcare system, and it offers coverage and reimbursement for treatments for cardiovascular disease (CVD). Taxes and donations from both employers and employees are used to pay for the system. Patients with CVD are eligible for coverage under the Assurance Maladie for a variety of treatments, including prescription drugs, diagnostic exams, and surgical procedures. However, there are some restrictions and limitations on the service. The French government regulates medication prices, and reimbursement for treatments for CVD is subject to stringent rules. Patients typically have to cover a part of their medical expenses through a co-payment or deductible.